By clicking below you acknowledge that you are navigating away from temaetfs.com and will be connected to temafunds. Tema Global Limited manages both domains. Please take note of Tema's privacy policy, terms of use, and disclosures that may vary between sites.
Start investing now
.svg){kind=small}
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Your are leaving temaetfs.com
Which fund are you interested in?
Life Sciences
HRTS 
GLP-1, Obesity & Cardiometabolic ETF
CANC
Oncology ETF
MNTL
Neuroscience and Mental Health ETF
Strategic Equity
TOLL
Monopolies and Oligopolies ETF
RSHO
American Reshoring ETF
VOLT(coming soon)
Tema Electrification ETF
LUX
Luxury ETF
.svg){kind=small}
.svg){kind=icon}
Back
Why HRTS ETF?
Underpenetrated, large market
Obesity is forecast to affect one in four people globally by 2035, and obesity-related conditions like diabetes and heart disease represent vast markets with significant growth potential.
Source: World Obesity Atlas, March 2023
Innovation
The Industry is witnessing significant progress in obesity therapeutics led by new drugs such as Ozempic and Wegovy, as well as a renaissance in
cardiovascular therapies through novel platforms like gene editing.
Research expertise
The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations.
Barriers to entry
In our view, many of the businesses identified have high barriers to entry, such as costly and lengthy clinical trials, large salesforce requirements in primary care markets, and substantial patent protection.
Uncorrelated
Performance of many companies relies on clinical or commercial success, which is an uncorrelated source of return.
Fund Overview
Fund Details
As of November 19, 2024
Primary Exchange
Nasdaq
Ticker
HRTS
AuM (USD)
$75,846,553
# of Holdings
45
Fund Inception Date
11/20/23
Gross Expense Ratio
0.99%
Net Expense Ratio*
0.75%
Implied Liquidity (# of shares)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
825,295
Implied Liquidity (USD)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
$25M
Shares Outstanding
2,480,000
Investment Advisor
Tema Global Limited
Sub-Investment Advisor
NEOS Investments, LLC
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/28/2027.
Fund Summary
The actively managed Tema GLP-1, Obesity & Cardiometabolic ETF seeks to provide long-term growth of capital by investing in GLP-1 and weight loss companies leading the fight against obesity and cardiometabolic diseases. Obesity is on the cusp of a revolution in therapeutics, while heart disease, the most common cause of death, is witnessing a renaissance of therapies driven by genetic insights and tools. The complex combination of scientific, regulatory and financing risks requires investment and scientific expertise to navigate this secular theme.
Source: Our World in Data, November 2023.
Portfolio Manager
Investment Partner
David K. Song, MD, PhD, CFA
David Song, Investment Partner, has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton.
How does the Tema HRTS ETF fit in a portfolio?
Investment Style Box
Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.
Potential Portfolio
Equity Allocation
3-5%
Equity Satellite
HRTS ETF
Equity core
Where could a position be funded from?
- Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.
- Provides a balanced exposure across key technologies and company risk profiles.
- Could replace a satellite or a growth-oriented position.
FAQ
Is the Tema GLP-1 & Weight Loss ETF open to option trading?
What companies are included in Tema's Obesity ETF?
How many holdings are in the Tema GLP-1 & Weight Loss ETF?
What is an obesity ETF?
What are the most successful weight loss drugs?
Which ETF has Novo Nordisk?
Which ETF has Eli Lilly?
Why should I invest in a Weight Loss Drug ETF?
What are the risks associated with investing in a Weight Loss Drug ETF?
What are some trends affecting the Weight Loss ETFs?
Which sectors are represented in a Cardiometabolic ETF?
How do Weight Loss ETFs select their holdings?
What makes Ozempic a significant component of Weight Loss ETF?
How to buy
*Neither Tema Global Limited nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.